Skip to main content
. 2021 Nov 19;30(3):1288–1299. doi: 10.1016/j.ymthe.2021.11.012

Figure 4.

Figure 4

Treatment with CPP-MOs increases MN numbers in the spinal cords of SMA mice

(A) Representative image of MN staining of spinal cords from SMA mice sacrificed at P10. ChAT antibody staining (red) of spinal cord MNs from symptomatic SMA mice treated at P5 with scr, naked MO, r6-MO, or RXR-MO sacrificed at P10. (B) Bar plot of MN numbers in SMA mice spinal cord at P10. Number of MNs was normalized to the scr-MO number as mean ± SEM. Statistical significance was determined using one-way ANOVA (∗∗∗p < 0.001, n = 60 slices, n = 4/group). (C) Representative image of MN staining in spinal cords from SMA mice treated with r6-MO or RXR-MO and sacrificed at P30. (D) Bar plot of MN numbers in spinal cords from SMA mice at P30. (E) Representative image of GFAP staining of spinal cords from wild-type mice and SMA mice treated with scr-MO, naked MO, r6-MO, or RXR-MO and sacrificed at P10. (F) Bar plot of gliosis levels in spinal cords from SMA mice at P10. The number of nuclei surrounded by GFAP was normalized to the scr-MO number and reported as mean ± SEM. Statistical significance was determined using one-way ANOVA (∗∗∗p < 0.001, n = 100 nuclei, n = 4/group). Scale bars, 50 μm (A and C) and 90 μm (E).